NLRP3 and atrial fibrillation: Mounting evidence suggests that SGLT2 inhibitors exert robust anti-inflammatory, antifibrotic, and antioxidative actions, many of which converge on suppression of the NLRP3 inflammasome—a central node in AF pathophysiology [192,193,194,195].